The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1515
ISSUE 1515
February 27, 2017
Issue 1515
- Auvi-Q Epinephrine Auto-Injector Returns
- Crisaborole (Eucrisa) for Atopic Dermatitis
- Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
- Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
- Kyleena - Another Hormonal IUD
- Drug Interaction: Clopidogrel and PPIs
- Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Auvi-Q Epinephrine Auto-Injector Returns
February 27, 2017 (Issue: 1515)
Auvi-Q (Kaléo; previously manufactured and
marketed by Sanofi), the epinephrine auto-injector
approved by the FDA in 2012 for emergency treatment
of anaphylaxis and voluntarily withdrawn in 2015
due to potential inaccurate dosage delivery,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.